Being inspired by the “REGONIVO/EPOC1603” trial (57), a phase Ib trial of anti-angiogenetic inhibitors (regorafenib) plus ICIs (nivolumab) for gastric and colorectal cancer, several clinical trials have been established to assess the therapeutic efficacy of a combination of VEGFR/VEGF inhibitors and ICIs in solid tumors, which we believe could benefit patients with IS1 COAD (58). Here, VEGFA is linked to colorectal cancer.